Payment overview · 2025
General Payments
$1,191.27
68 reported records · 19 companies
Healthcare provider profile · identity verified
Harrison Clay Carter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALMA, GA · NPI 1043221492
Verified facts
What the public records show
CMS Open Payments records show Harrison Clay Carter, MD received $1,191.27 in general payments during 2025 across 68 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.40 | 17.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $173.52 | 14.6% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.35 | 11.6% | 9 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $103.27 | 8.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.72 | 7.4% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $86.85 | 7.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.16 | 6.1% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $60.27 | 5.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.78 | 4.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.40 | 2.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.82 | 2.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.81 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.59 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.35 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.02 | 1.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.81 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.46 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.02 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.67 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,191.27 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $145.40 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $141.91 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $138.35 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.99 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $103.27 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $86.85 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $60.27 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.78 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.20 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.52 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $37.83 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.82 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 363 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 249 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 146 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 360 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 218 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
104 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
164 | 29 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
249 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 30 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
363 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
146 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
360 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
218 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
363 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
51 | 49 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1561 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1352 | 295 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1141 | 232 |
| Gabapentin | Gabapentin | 973 | 218 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 925 | 130 |
| Montelukast Sodium | Montelukast Sodium | 899 | 194 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 897 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 882 | 201 |
| Atorvastatin Calcium | Atorvastatin Calcium | 830 | 187 |
| Omeprazole | Omeprazole | 698 | 155 |
| Metoprolol Succinate | Metoprolol Succinate | 685 | 153 |
| Lisinopril | Lisinopril | 638 | 148 |
| Clonazepam | Clonazepam | 630 | 108 |
| Tramadol Hcl | Tramadol Hcl | 625 | 144 |
| Alprazolam | Alprazolam | 610 | 109 |
| Famotidine | Famotidine | 571 | 108 |
| Losartan Potassium | Losartan Potassium | 551 | 138 |
| Duloxetine Hcl | Duloxetine Hcl | 524 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 505 | 113 |
| Furosemide | Furosemide | 465 | 125 |
| Simvastatin | Simvastatin | 448 | 101 |
| Clopidogrel | Clopidogrel Bisulfate | 445 | 97 |
| Potassium Chloride | Potassium Chloride | 439 | 97 |
| Meloxicam | Meloxicam | 434 | 101 |
| Methylprednisolone | Methylprednisolone | 419 | 288 |
| Metformin Hcl | Metformin Hcl | 414 | 101 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 373 | 81 |
| Eliquis | Apixaban | 363 | 64 |
| Mounjaro | Tirzepatide | 360 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 342 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 338 | 82 |
| Trazodone Hcl | Trazodone Hcl | 331 | 70 |
| Tizanidine Hcl | Tizanidine Hcl | 313 | 74 |
| Ropinirole Hcl | Ropinirole Hcl | 309 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 308 | 108 |
| Celecoxib | Celecoxib | 295 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 293 | 51 |
| Carvedilol | Carvedilol | 277 | 66 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 266 | 209 |
| Sertraline Hcl | Sertraline Hcl | 262 | 54 |
| Farxiga | Dapagliflozin Propanediol | 249 | 46 |
| Testosterone Cypionate | Testosterone Cypionate | 248 | 54 |
| Allopurinol | Allopurinol | 241 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 222 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 218 | 54 |
| Ozempic | Semaglutide | 218 | 50 |
| Cefdinir | Cefdinir | 213 | 164 |
| Hydralazine Hcl | Hydralazine Hcl | 209 | 33 |
| Ondansetron Odt | Ondansetron | 201 | 92 |
| Lorazepam | Lorazepam | 196 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 179 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 172 | 39 |
| Bupropion Xl | Bupropion Hcl | 171 | 39 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 169 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 168 | 68 |
| Xarelto | Rivaroxaban | 165 | 26 |
| Synthroid | Levothyroxine Sodium | 164 | 29 |
| Donepezil Hcl | Donepezil Hcl | 162 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 160 | 30 |
| Temazepam | Temazepam | 160 | 33 |
| Megestrol Acetate | Megestrol Acetate | 148 | 34 |
| Meclizine Hcl | Meclizine Hcl | 147 | 57 |
| Jardiance | Empagliflozin | 146 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 29 |
| Fenofibrate | Fenofibrate | 140 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 138 | 27 |
| Januvia | Sitagliptin Phosphate | 134 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 134 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 44 |
| Amoxicillin | Amoxicillin | 130 | 96 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 125 | 25 |
| Eszopiclone | Eszopiclone | 124 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 119 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 118 | 91 |
| Azithromycin | Azithromycin | 118 | 85 |
| Diazepam | Diazepam | 118 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 115 | 33 |
| Ezetimibe | Ezetimibe | 115 | 26 |
| Glimepiride | Glimepiride | 113 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 109 | 20 |
| Buspirone Hcl | Buspirone Hcl | 108 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 26 |
| Estradiol | Estradiol | 104 | 25 |
| Linzess | Linaclotide | 104 | 22 |
| Glipizide Er | Glipizide | 103 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 103 | 72 |
| Topiramate | Topiramate | 103 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 101 | 18 |
| Ibuprofen | Ibuprofen | 101 | 32 |
| Warfarin Sodium | Warfarin Sodium | 97 | 15 |
| Clonidine Hcl | Clonidine Hcl | 96 | 21 |
| Pregabalin | Pregabalin | 96 | 26 |
| Fluconazole | Fluconazole | 93 | 59 |
| Prednisone | Prednisone | 92 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 89 | 17 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 87 | 19 |
| Levetiracetam | Levetiracetam | 87 | 13 |
| Nifedipine Er | Nifedipine | 86 | 20 |
| Terazosin Hcl | Terazosin Hcl | 86 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 16 |
| Entresto | Sacubitril/Valsartan | 77 | 19 |
| Clonidine | Clonidine | 76 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 75 | 59 |
| Spironolactone | Spironolactone | 75 | 22 |
| Baclofen | Baclofen | 74 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 74 | 39 |
| Divalproex Sodium | Divalproex Sodium | 74 | 14 |
| Fentanyl | Fentanyl | 73 | 12 |
| Finasteride | Finasteride | 73 | 17 |
| Olanzapine | Olanzapine | 73 | 12 |
| Memantine Hcl | Memantine Hcl | 72 | 13 |
| Promethazine Hcl | Promethazine Hcl | 72 | 27 |
| Nystatin | Nystatin | 71 | 41 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 69 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 58 |
| Metoclopramide Hcl | Metoclopramide Hcl | 68 | 15 |
| Alendronate Sodium | Alendronate Sodium | 66 | 11 |
| Glipizide | Glipizide | 66 | 12 |
| Myrbetriq | Mirabegron | 64 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 62 | 36 |
| Ketoconazole | Ketoconazole | 62 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 62 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 59 | suppressed |
| Digoxin | Digoxin | 59 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 59 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 58 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 13 |
| Torsemide | Torsemide | 56 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 55 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 54 | 11 |
| Rybelsus | Semaglutide | 54 | 12 |
| Trulicity | Dulaglutide | 54 | 12 |
| Progesterone | Progesterone, Micronized | 53 | 12 |
| Ramipril | Ramipril | 53 | suppressed |
| Valsartan | Valsartan | 53 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 52 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 51 | 49 |
| Lansoprazole | Lansoprazole | 50 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 50 | suppressed |
| Colchicine | Colchicine | 48 | 21 |
| Sucralfate | Sucralfate | 48 | 14 |
| Metformin Hcl Er | Metformin Hcl | 47 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 45 | 11 |
| Levofloxacin | Levofloxacin | 45 | 38 |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 44 | 42 |
| Rivastigmine | Rivastigmine Tartrate | 44 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 43 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 42 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Cephalexin | Cephalexin | 41 | 28 |
| Methocarbamol | Methocarbamol | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 39 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Naproxen | Naproxen | 36 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 25 |
| Levemir Flexpen | Insulin Detemir | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 20 |
| Alcohol Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 21 |
| Anastrozole | Anastrozole | 26 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 26 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Cartia Xt | Diltiazem Hcl | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Indomethacin | Indomethacin | 24 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 24 | 11 |
| Azelastine Hcl | Azelastine Hcl | 23 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 23 | 23 |
| Risperidone | Risperidone | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 15 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 22 | 13 |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Leflunomide | Leflunomide | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Desloratadine | Desloratadine | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Indomethacin Er | Indomethacin | 19 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 18 | 12 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 18 | 14 |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Dexilant | Dexlansoprazole | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 15 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nucynta Er | Tapentadol Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Betaseron | Interferon Beta-1b | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | 13 |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Cozaar | Losartan Potassium | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,191.27 · 68 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error